

**EPV-326****Real-world evidence on 24 months of erenumab treatment of migraine patients in Switzerland: Long-term data from SQUARE**

E. Schäfer<sup>1</sup>, I. Meyer<sup>1</sup>, M. Arzt<sup>1</sup>, A. Gantenbein<sup>2</sup>  
<sup>1</sup>Novartis Pharma Schweiz AG, Rotkreuz, Switzerland,  
<sup>2</sup>Research and Pain Unit, ZURZACH Care, Bad Zurzach, Switzerland and Department of Neurology, University Hospital Zurich, Zurich, Switzerland

**EPV-327****Pituitary apoplexy during pregnancy, a potentially dangerous headache**

C. Gómez López de San Román, M. Capra,  
 L. Caballero Sánchez, D. Cerdán Santacruz,  
 P. Gil Armada, J. Berrio Suaza, A. Castrillo Sanz,  
 A. Mendoza Rodriguez, F. Rodriguez Sanz  
 Hospital Complex of Segovia, Neurology, Segovia, Spain

**EPV-328****Evaluation of concomitant preventive treatments in patients with migraine with anti-CGRP therapies: the PREVENAC study**

A. Gonzalez-Martinez, N. López Alcaide,  
 I. Fernández Lázaro, S. Quintas, J. Vivancos, A. Gago-  
 Veiga  
 Headache Unit, Neurology Department, Hospital Universitario de la Princesa & Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid, Madrid, Spain

**EPV-329****GENDER DIFFERENCES OF BDNF DURING CLINICAL COURSE OF MIGRAINE**

B. Holmuratova, N. Rashidova, K. Khalimova,  
 G. Rakhmatullayeva  
 Tashkent medical academy, Tashkent, Uzbekistan

**EPV-330****Influencing factors of the quality of life among migraine patients in Szeged, Hungary**

F. Horváth<sup>1</sup>, A. Csáti<sup>2</sup>, J. Tajti<sup>2</sup>, D. Szok<sup>2</sup>, G. Fehér<sup>3</sup>  
<sup>1</sup>Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary, <sup>2</sup>Department of Neurology, University of Szeged, Szeged, Hungary, <sup>3</sup>Clinical Center, University of Pécs, Pécs, Hungary

**EPV-331****Management of Migraine Without Aura in Adolescents: The Efficacy of Flunarizine in a Turkish Cohort**

E. Ilik<sup>1</sup>, D. Ertem<sup>2</sup>  
<sup>1</sup>Department of Neurology, KTO University, Medicana Hospital, Konya, Turkey, <sup>2</sup>Department of Neurology, Silivri Anadolu Hospital, Istanbul, Turkey

**EPV-332****Females are 6 times more prevalent among patients with medication overuse headache in a tertiary headache centre**

Y. Knyazeva, E. Lebedeva  
 The Ural State Medical University, International Headache Center "Europe-Asia", Yekaterinburg, Russian Federation

**EPV-333****The Impact of the COVID-19 Pandemic on the Migraine Patients**

O. Kopchak  
 Kyiv Medical University, Kyiv, Ukraine

**EPV-334****Abstract withdrawn****EPV-335****Gender-dependent differences in patients with migraine treated with anti-cgrp monoclonal: a real-life pilot study**

V. Laterza<sup>1</sup>, G. Idone<sup>1</sup>, D. Tedeschi<sup>1</sup>, M. Pasquale<sup>1</sup>,  
 P. Bruno<sup>1</sup>, G. Spano<sup>1</sup>, F. Bono<sup>2</sup>  
<sup>1</sup>Institute of Neurology, Magna Graecia University, Catanzaro, Italy, <sup>2</sup>Center for Headache and Intracranial Pressure Disorders, A. O. U. "Mater Domini", Catanzaro, Italy

**EPV-336****Abstract withdrawn****EPV-337****Headache in acute stroke: a cross-sectional study in Bishkek, Kyrgyzstan**

I. Lutsenko  
 Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan